An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed 195 enrolled Genentech, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

Timeline

Start: 2020-03-09
Primary completion: 2026-05-27
Completion: 2026-05-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	—	Intravenous
Subject	XmAb24306	Unknown	—	Intravenous

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications